RT Journal Article
SR Electronic
T1 Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: a randomised, placebo-controlled, dose-ranging study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.19.20248611
DO 10.1101/2021.01.19.20248611
A1 Goepfert, Paul A
A1 Fu, Bo
A1 Chabanon, Anne-Laure
A1 Bonaparte, Matthew I
A1 Davis, Matthew G
A1 Essink, Brandon J
A1 Frank, Ian
A1 Haney, Owen
A1 Janosczyk, Helene
A1 Keefer, Michael C
A1 Koutsoukos, Marguerite
A1 Kimmel, Murray A
A1 Masotti, Roger
A1 Savarino, Stephen J
A1 Schuerman, Lode
A1 Schwartz, Howard
A1 Sher, Lawrence D
A1 Smith, Jon
A1 Tavares-Da-Silva, Fernanda
A1 Gurunathan, Sanjay
A1 DiazGranados, Carlos A
A1 De Bruyn, Guy
YR 2021
UL http://medrxiv.org/content/early/2021/01/20/2021.01.19.20248611.abstract
AB Background Effective vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are urgently needed. CoV2 preS dTM is a stabilised pre-fusion S protein vaccine produced in a baculovirus expression system. We present interim safety and immunogenicity results of the first-in-human study of the CoV2 preS dTM vaccine with two different adjuvant formulations.Methods This Phase I/II, randomised, double-blind study (NCT04537208) is being conducted in healthy, SARS-CoV-2-seronegative adults in the USA. Participants were stratified by age (18–49 and ≥50 years) and randomised to receive one (on Day[D]1) or two doses (D1, D22) of placebo or candidate vaccine, containing: low-dose (LD, effective dose 1.3 µg) or high-dose (HD, 2.6 µg) antigen with adjuvant AF03 (Sanofi Pasteur) or AS03 (GlaxoSmithKline); or unadjuvanted HD (18–49 years only). Safety was assessed up to D43. SARS-CoV-2 neutralising and binding antibody profiles were assessed in D1, D22 and D36 serum samples.Findings The interim safety analyses included 439/441 randomised participants. There were no related unsolicited immediate AEs, serious AEs, medically attended AEs classified as severe, or AE of special interest. More grade 3 solicited reactions were reported than expected after the second dose in the adjuvanted vaccine groups. Neutralising and binding antibody responses after two vaccine doses were higher in adjuvanted versus unadjuvanted groups, in AS03-versus AF03-adjuvanted groups, in HD versus LD groups, and in younger versus older age strata.Interpretation The lower than expected immune responses, especially in the older age stratum, and the higher than anticipated reactogenicity post dose 2 were likely due to a higher than anticipated host cell protein content and lower than planned antigen dose in the clinical material. Further development of the AS03-adjuvanted candidate vaccine will focus on identifying the optimal antigen formulation and dose.Competing Interest StatementBF, ALC, MIB, OH, HJ, RM, SJS, JS, SG, CAD and GDB are Sanofi Pasteur employees and may hold stock. MK, LS and FTDS are employed by the GlaxoSmithKline (GSK) group of companies. MK, LS and FTDS hold restricted shares in the GSK group of companies. IF reports grants from Janssen and personal fees from Gilead and ViiV/ GlaxoSmithKline. PAG, BJE, MCK, MAK, MGD, LDS and HS declare that they have no conflict of interest.Clinical TrialNCT04537208Funding StatementFunding was provided Sanofi Pasteur and by the US Government through Biomedical Advanced Research and Development Authority (BARDA) under contract HHSO100201600005I.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:https://www.advarra.com/ Pro00045646 approval letter dated 31Jul2020.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesQualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymised and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com. https://www.clinicalstudydatarequest.com